The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Brief Title: A Phase 1, First in Human Study of TORL-4-500 in Patients With Advanced Cancer
Official Title: A Phase 1, First in Human Study of TORL-4-500 in Patients With Advanced Cancer
Study ID: NCT06005740
Brief Summary: This first-in-human study will evaluate the safety, tolerability, pharmacokinetics, and antitumor activity of TORL-4-500 in patients with advanced cancer
Detailed Description:
Minimum Age: 18 Years
Eligible Ages: ADULT, OLDER_ADULT
Sex: ALL
Healthy Volunteers: No
UCLA - JCCC Clinical Research Unit, Los Angeles, California, United States
Name: Stephen Letrent, PharmD, PhD
Affiliation: TORL Biotherapeutics, LLC
Role: STUDY_DIRECTOR